A Phase I Study of Ridaforolimus and Vorinostat in Patients With Advanced Solid Tumors or Lymphoma (IND 109130)

Trial Profile

A Phase I Study of Ridaforolimus and Vorinostat in Patients With Advanced Solid Tumors or Lymphoma (IND 109130)

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2015

At a glance

  • Drugs Ridaforolimus (Primary) ; Vorinostat (Primary)
  • Indications Carcinoid tumour; Lymphoma; Oesophageal cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Nov 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 04 Sep 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2016 as per ClinicalTrials.gov record.
    • 25 Mar 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top